Choksi Laboratories Receives USFDA Form 483

INDORE — Choksi Laboratories Limited announced that the United States Food and Drug Administration (USFDA) has concluded a routine inspection of the company's central laboratory facility located in Indore, Madhya Pradesh.

The audit, which took place from August 17 to August 20, 2026, concluded with the issuance of a Form 483 containing four procedural observations. Management confirmed that the laboratory's technical teams are actively reviewing the findings to formulate comprehensive corrective and preventative action (CAPA) responses within the mandated regulatory window.

Regulatory Audit and Laboratory Operations

As an independent analytical and contract testing laboratory, Choksi Laboratories serves pharmaceutical, food, and chemical sectors by providing statutory quality control testing, stability studies, and compliance verification. Routine regulatory oversight by the USFDA ensures that contract testing facilities adhere strictly to current good laboratory practices (cGLP) and current good manufacturing practices (cGMP).

According to official corporate disclosures, stock exchange filings, and regulatory updates:

• Audit Dates: The inspection of the central laboratory in Indore was conducted between August 17 and August 20, 2026.

• Regulatory Outcome: The USFDA issued a Form 483 detailing four specific observations upon conclusion of the review.

• Management Response: Company executives stated that technical and quality assurance personnel are preparing responses to address each observation promptly.

• Operational Continuity: Analytical testing services and laboratory operations continue uninterrupted while corrective action plans are finalized.

Official Sources Section

• BSE India Corporate Disclosures: Official material event notifications, regulatory filings, and corporate statements submitted by Choksi Laboratories.

• National Stock Exchange of India (NSE): Exchange compliance archives and corporate disclosure updates.

• U.S. Food and Drug Administration (USFDA): Regulatory guidelines, laboratory inspection protocols, and compliance framework documentation.

Quote Section

According to statements released by company representatives regarding the conclusion of the inspection:

"The USFDA has successfully concluded its inspection at our central laboratory in Indore, issuing a Form 483 with four observations. We are fully committed to addressing these observations and submitting our comprehensive corrective action plan within the stipulated regulatory timeline."

Why It Matters

For pharmaceutical manufacturers, regulatory compliance auditors, and institutional investors, maintaining flawless standing at contract testing laboratories is essential for international supply chain integrity. Swift resolution of USFDA observations ensures uninterrupted analytical certification for drug products destined for regulated global markets.

Key Facts at a Glance

• Company: Choksi Laboratories Limited.

• Facility Location: Central Laboratory, Indore, Madhya Pradesh.

• Audit Window: August 17–20, 2026.

• Outcome: Form 483 issued with four observations.

FAQ Section

What is the significance of a USFDA Form 483 for a testing lab? A Form 483 highlights procedural or operational conditions observed by investigators that may require corrective action, but it does not represent a final regulatory penalty or a ban on operations.

How many observations did Choksi Laboratories receive? The USFDA inspection at the Indore laboratory concluded with four observations documented under Form 483.

Does this inspection halt the laboratory's testing services? No, routine analytical testing and laboratory operations continue as scheduled while the company formulates its formal response.

Where can stakeholders review official corporate disclosures? Official regulatory notifications and exchange filings are published directly on the BSE and NSE portal archives.

Source: BSE India, NSE India, USFDA, TradingView